Cleavable PEGylation: a strategy for overcoming the "PEG dilemma" in efficient drug delivery

被引:291
作者
Fang, Yan [1 ]
Xue, Jianxiu [1 ]
Gao, Shan [1 ]
Lu, Anqi [1 ]
Yang, Dongjuan [1 ]
Jiang, Hong [1 ]
He, Yang [1 ]
Shi, Kai [1 ]
机构
[1] Shenyang Pharmaceut Univ, Sch Pharmaceut Sci, Dept Pharmaceut, Shenyang 110016, Liaoning, Peoples R China
基金
中国国家自然科学基金;
关键词
PEGylation; cleavable PEG; drug delivery; nanocarriers; strategy; ACCELERATED BLOOD CLEARANCE; TAT-PEPTIDE; INTRACELLULAR DELIVERY; TARGETED DELIVERY; CANCER-THERAPY; PHARMACEUTICAL NANOCARRIERS; SENSITIVE LIPOSOME; HYDRAZONE LINKAGE; TRIGGERED RELEASE; ABC PHENOMENON;
D O I
10.1080/10717544.2017.1388451
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To prolong the circulation time of drug, PEGylation has been widely used via the enhanced permeability and retention (EPR) effect, thereby providing new hope for better treatment. However, PEGylation also brings the "PEG dilemma", which is difficult for the cellular absorption of drugs and subsequent endosomal escape. As a result, the activity of drugs is inevitably lost after PEG modification. To achieve successful drug delivery for effective treatment, the crucial issue associated with the use of PEG-lipids, that is, "PEG dilemma" must be addressed. In this paper, we introduced the development and application of nanocarriers with cleavable PEGylation, and discussed various strategies for overcoming the PEG dilemma. Compared to the traditional ones, the vehicle systems with different environmental-sensitive PEG-lipids were discussed, which cleavage can be achieved in response to the intracellular as well as the tumor microenvironment. This smart cleavable PEGylation provides us an efficient strategy to overcome "PEG dilemma", thereby may be a good candidate for the cancer treatment in future.
引用
收藏
页码:22 / 32
页数:11
相关论文
共 108 条
[71]   Endosomal Escape: A Bottleneck in Intracellular Delivery [J].
Shete, Harshad K. ;
Prabhu, Rashmi H. ;
Patravale, Vandana B. .
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY, 2014, 14 (01) :460-474
[72]   Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells [J].
Shimizu, Taro ;
Mima, Yu ;
Hashimoto, Yosuke ;
Ukawa, Masami ;
Ando, Hidenori ;
Kiwada, Hiroshi ;
Ishida, Tatsuhiro .
IMMUNOBIOLOGY, 2015, 220 (10) :1151-1160
[73]   Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids [J].
Shin, J ;
Shum, P ;
Thompson, DH .
JOURNAL OF CONTROLLED RELEASE, 2003, 91 (1-2) :187-200
[74]   Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes [J].
Song, LY ;
Ahkong, QF ;
Rong, Q ;
Wang, Z ;
Ansell, S ;
Hope, MJ ;
Mui, B .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2002, 1558 (01) :1-13
[75]   Facile Generation of Tumor-pH-Labile Linkage-Bridged Block Copolymers for Chemotherapeutic Delivery [J].
Sun, Chun-Yang ;
Liu, Yang ;
Du, Jin-Zhi ;
Cao, Zhi-Ting ;
Xu, Cong-Fei ;
Wang, Jun .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2016, 55 (03) :1010-1014
[76]   PEGylation improves the receptor-mediated transfection efficiency of peptide-targeted, self-assembling, anionic nanocomplexes [J].
Tagalakis, Aristides D. ;
Kenny, Gavin D. ;
Bienemann, Alison S. ;
McCarthy, David ;
Munye, Mustafa M. ;
Taylor, Hannah ;
Wyatt, Marcella J. ;
Lythgoe, Mark F. ;
White, Edward A. ;
Hart, Stephen L. .
JOURNAL OF CONTROLLED RELEASE, 2014, 174 :177-187
[77]   Liposomes co-modified with cholesterol anchored cleavable PEG and octaarginines for tumor targeted drug delivery [J].
Tang, Jie ;
Fu, Han ;
Kuang, Qifang ;
Zhang, Li ;
Zhang, Qianyu ;
Liu, Yayuan ;
Ran, Rui ;
Gao, Huile ;
Zhang, Zhirong ;
He, Qin .
JOURNAL OF DRUG TARGETING, 2014, 22 (04) :313-326
[78]   Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting [J].
Terada, T ;
Iwai, M ;
Kawakami, S ;
Yamashita, F ;
Hashida, M .
JOURNAL OF CONTROLLED RELEASE, 2006, 111 (03) :333-342
[79]   Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers [J].
Torchilin, Vladimir P. .
ADVANCED DRUG DELIVERY REVIEWS, 2008, 60 (4-5) :548-558
[80]   Targeted pharmaceutical nanocarriers for cancer therapy and Imaging [J].
Torchilin, Vladimir P. .
AAPS JOURNAL, 2007, 9 (02) :E128-E147